✕
Gain access to exclusive preclinical content.
Complete the form below. We'll assign a user name and password, then send you a link. Thanks!

Get Access Register

EXCLUSIVE PRECLINICAL CONTENT.
You must log in to access content on this page. Or click here to request access.
 简体中文
(Simplified Chinese) 繁體中文
(Traditional Chinese)
AT1-AA (Angiotensin II Type 1 Receptor Agonistic Autoantibody) Blockade Prevents Preeclamptic Symptoms in Placental Ischemic Rats
Wednesday, November 27th, 2019
Cunningham MW Jr, Castillo J, Ibrahim T, Cornelius DC, Campbell N, Amaral L, Vaka VR, Usry N, Williams JM, LaMarca B, “ AT1-AA (Angiotensin II
The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk
Thursday, November 21st, 2019
Eva-Maria Pastor-Arroyo, Nicole Gehring, Christiane Krudewig, Sarah Costantino, Carla Bettoni, Thomas Knöpfel, Sibylle Sabrautzki, Bettina Lorenz-Depiereux, Johanne Pastor, Tim M. Strom, Martin Hrabě de Angelis,
Long-Lasting RNAi Therapeutics Targeting Angiotensinogen Induces a Robust and Durable Antihypertensive Effect
Sunday, November 10th, 2019
Estrellita Uijl, Katrina M. Mirabito Colafella, Ewout J. Hoorn, Jae B. Kim, Donald J. Foster, Alexander H. Danser, “Long-Lasting RNAi Therapeutics Targeting Angiotensinogen Induces a
Altered microRNA regulation of short chain fatty acid receptors in the hypertensive kidney is normalized with hydrogen sulfide supplementation
Wednesday, October 30th, 2019
Gregory J. Weber, Jaleyea Foster, Sathnur B. Pushpakumar, Utpal Sen, “Altered microRNA regulation of short chain fatty acid receptors in the hypertensive kidney is normalized
Combined AT2 Receptor Stimulation AT1 Receptor Blockade Does Not Cause Renal Dysfunction
Monday, October 21st, 2019
Dhaniel Baraldi, Lucinda M Hilliard, Tracey A Gaspari, Kate M Denton, Robert E Widdop, “Combined AT2 Receptor Stimulation AT1 Receptor Blockade Does Not Cause Renal
Exposure to placental ischemia impairs postpartum maternal renal and cardiac function in rats
Thursday, October 17th, 2019
Nina D. Paauw, Jaap A Joles, Frank T. Spradley, Bhavisha Bakrania, Zsuzsanna K Zellenger, Arie Franx, Marianne C. Verhaar, Joey P. Granger, A. Titia Lely,
Renal Fibrosis and Tubular Transport Adaptation Caused by Cardiac Arrest and Cardiopulmonary Resuscitation (CA/CPR) in Mice
Sunday, October 6th, 2019
Michael Hutchens, Rumie Wakasaki, Ian P. Coe,Mohammed Z. Ferdaus, James A. McCormick, Sharon Anderson, “Renal Fibrosis and Tubular Transport Adaptation Caused by Cardiac Arrest and
Chronic recurrent dehydration associated with periodic water intake exacerbates hypertension and promotes renal damage in male spontaneously hypertensive rats
Wednesday, September 25th, 2019
Hilliard LM, Colafella KM, Bulmer LL, Puelles VG, Singh RR, Ow CP, Gaspari T, Drummond GR, Evans RG, Vinh A, Denton KM, “Chronic recurrent dehydration
Intrarenal ACE as a Catalyst for Hypertension
Friday, September 20th, 2019
Gonzales-Villaobos R.A., “Intrarenal ACE as a Catalyst for Hypertension,” J. Am. Soc. Nephrol. Kidney Week 2016.
Intrauterine Growth Restriction Programs a Greater Age-related Decline in Renal Function Associated With Increased Susceptibility to Chronic Renal Injury
Thursday, September 12th, 2019
Ashley D Newsome, Gwendolyn K Davis, Norma B Ojeda, Barbara T Alexander, “ Intrauterine Growth Restriction Programs a Greater Age-related Decline in Renal Function Associated
Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL/6 mice
Monday, September 9th, 2019
SR Mulay, Eberhard JN, Pfann V. et al,“Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL/6 mice,” Am J Physiol Renal Physiol;
Placental Growth Factor Administration Abolishes Placental Ischemia-Induced Hypertension
Saturday, September 7th, 2019
Spradley FT, Tan AY, Joo WS, Daniels G, Kussie P, Karumanchi SA, Granger JP.,“Placental Growth Factor Administration Abolishes Placental Ischemia-Induced Hypertension,” Hypertension. 2016 Apr;67(4):740-7. doi:
Lack of an effect of nephron-specific deletion of adenylyl cyclase 3 on renal sodium and water excretion or arterial pressure
Thursday, August 22nd, 2019
Kittikulsuth W, Stuart D, Van Hoek A.V., Kohan D.E., “Lack of an effect of nephron-specific deletion of adenylyl cyclase 3 on renal sodium and water
Mutation of the Nicotinamide Adenine Dinucleotide Phosphate-Oxidase Subunit p67phox Protects the Dahl-S Rat From Salt-Induced Reductions in Medullary Blood Flow and Glomerular Filtration Rate
Sunday, August 18th, 2019
C. Evans LC, Ryan RP, Broadway E, Skelton MM, Kurth T, Cowley AW. Null, “Mutation of the Nicotinamide Adenine Dinucleotide Phosphate-Oxidase Subunit p67phox Protects the
Salt Sensitivity in Response to Renal Injury Requires Renal Angiotensin-Convertin Enzyme
Friday, August 16th, 2019
Giani JF, Bernstein KE, Janjulia T, Han J, Toblli JE, Shen XZ, Rodriguez-Iturbe B, McDonough AA, Gonzalez-Villalobos RA, “Salt Sensitivity in Response to Renal Injury
Renal Angiotensin-Converting Enzyme Is Essential for the Hypertension Induced by Nitric Oxide Synthesis Inhibition
Sunday, August 4th, 2019
Giani JF, Janjulia T, Kamat N, Seth DM, Blackwell WB, Shah KH, Shen XZ, Fuchs S, Delpire E, Toblli JE, Bernstein KE, McDonough AA, Gonzalez-Villalobos
Renal generation of angiotensin II and the pathogenesis of hypertension
Saturday, August 3rd, 2019
C. Giani JF, Janjulia T, Taylor B, Bernstein EA, Shah K, Shen XZ, McDonough AA, Bernstein KE, Gonzalez-Villalobos RA, “Renal generation of angiotensin II and
Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression
Tuesday, July 30th, 2019
Trudu M, Janas S, Lanzani C, Debaix H, Schaeffer C, Ikehata M, Citterio L, Demaretz S, Trevisani F, Ristagno G, Glaudemans B, Laghmani K, Dell’Antonio
Progression of glomerular filtration rate reduction determined in conscious Dahl salt-sensitive hypertensive rats
Monday, July 29th, 2019
Cowley AW, Ryan RP, Kurth T, Skelton MM, Schock-Kusch D, Gretz N, “Progression of glomerular filtration rate reduction determined in conscious Dahl salt-sensitive hypertensive rats,”

United States
MediBeacon Inc.
425 N. New Ballas Road
Suite 100
St. Louis, MO 63141
P: (314) 269-5808

Germany
MediBeacon GmbH
Franz-Volhard-Straße 8
68167 Mannheim
P: +49 621 32465472

Greater China
(Commercial Partner)
Huadong Medicine Co., Ltd
No.866, Moganshan Road
Hangzhou, ZJ 310011
P: +86 (0)571-89908581
Email: info@eastchinapharm.com

Science How it Works R&D Platform Product Pipeline Patent Estate Preclinical Clinical Focus Areas Nephrology Gastroenterology Ophthalmology Surgery In Discovery
Publications MediBeacon Publications Preclinical Publications Industry Literature Company History People By The Numbers Quality Commitment News/Media Careers Contact Get Updates Investors General Questions

*MediBeacon products are in various stages of development.

Patent Marking | Website Terms of Use | Terms and Conditions | Warranty | Privacy Policy | © 2026 MediBeacon All Rights Reserved.